Genovis is launching a new enzyme product

Genovis is introducing a new enzyme that is being marketed under the name
GingisKHAN™ for customers primarily in the pharmaceutical industry for
characterization of antibody-based drugs.
Genovis’ products are marketed under the name SmartEnzymes and are used in the
biotech and pharmaceutical industries for characterization of biologics. Today,
about 80% of all antibody-based drugs are based on IgG1 molecules, human
immunoglobulin of subclass 1, which is also the most common antibody in the
natural composition of human antibodies. GingisKHAN is an enzyme, cysteine
protease, which splits IgG1 very rapidly at a specific location in the molecule.
The product complements FabRICATOR® and FabULOUS®, but can also be used in
studies of intact Fab and Fc fragments. This is important for Genovis’ customers
in assays such as in crystallization, studies of Fab parts of bispecific
antibodies and for studies of the three-dimensional structure of antibodies.
Next week GingisKHAN will be presented at the Analytical Technologies Europe
conference in Berlin: Symposium on the Practical Applications including CE, LC
and MS in the Biopharmaceutical Industry.

“Genovis’ product FabRICATOR entailed a paradigm shift for the methods that the
pharmaceutical industry uses to characterize and analyze biological medicines.
The new technology is now accepted and on the path to becoming more broadly
established. Our strategy is to ensure that we are first with the next
generation of products that support this rapid development. We prioritize
products that can further improve analysis results for customers and that can
work on several different proteins, and not just antibody-based drugs. In spring
2015 we will launch four new products, which will mean that we are doubling our
selection of enzyme products for customers. GingisKHAN is the first out, in part
because our customers asked for an enzyme with precisely these characteristics
and in part because we see that the product has the potential to attract new
customers. We believe that the market for this enzyme can reach the same
potential as FabRICATOR,” says Sarah Fredriksson, CEO of Genovis

For more information about GingisKHAN: www.genovis.com/GingisKHAN
For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel:
0046 (0)46 -101235 sarah.fredriksson@genovis.com
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00